Cipher Pharmaceuticals Inc. (TSX: CPH)

Market Cap	376.68M
Revenue (ttm)	35.75M
Net Income (ttm)	21.42M
Shares Out	25.59M
EPS (ttm)	0.85
PE Ratio	17.22
Forward PE	14.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,111
Open	14.78
Previous Close	14.65
Day's Range	14.50 - 14.87
52-Week Range	5.35 - 19.69
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwante...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CPH

Financial Performance

In 2023, Cipher Pharmaceuticals's revenue was $21.16 million, an increase of 2.36% compared to the previous year's $20.68 million. Earnings were $20.38 million, a decrease of -23.48%.

Financial numbers in USD